651 results about "Dosing regimen" patented technology

Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

The invention relates to the technical field of tumor treatment, in particular to an intelligent decision-making system for tumor precise targeted medication based on individual mutation information, which comprises a data processing layer, a variation annotation and function prediction layer, a knowledge base integration layer and a scheme decision-making engine and report visualization module. According to the intelligent decision-making system for tumor precise targeted medication based on individual mutation information, a rule engine and a prediction model are combined, dynamic priority ranking is output, multi-model fusion decision making is achieved, and clinical scene deep adaptation is achieved by predicting primary and secondary drug resistance, calculating liver and kidney function adjusting dosage and generating a combined medication time sequence scheme; through an individualized drug delivery scheme, combination drug use optimization is achieved, a visual clinical report is generated, clinical executable operation is further strengthened, and through algorithm quantification, a dynamic knowledge graph, AI auxiliary decision making and a clinical operation closed loop, the next-generation technical research direction of a tumor precise drug use system can be represented.

The invention provides a chronic disease co-patient accurate medication real-time management system based on an AI large model, and the system comprises accurate medication guided by the AI large model, through the mathematical modeling and simulation technology, the related information of patients, medicines and diseases is integrated, and accurate medication is guided. According to the method, the administration scheme can be formulated more accurately, the curative effect is improved, side effects are reduced, a patient medication report is provided for physicians and pharmacists, the physicians and pharmacists can dynamically master patient medication information in real time, reference is provided for the physicians to formulate the next medication scheme, and the treatment effect on chronic disease patients is improved.

Provided herein are variant α4β7 integrin antibodies and methods of use.

The invention provides an automatic determination method and system for an individualized medication adjustment dosage, and the method comprises the steps: calculating an initial administration scheme through employing a weighting result of a first atrioventricular model and a second atrioventricular model based on the physiological data and medication types of a patient; meanwhile, when the initial administration scheme of the patient is poor in effect or has adverse reaction, the administration scheme of the patient is adjusted. Compared with the prior art, the method has the advantages that the medication dosage can be accurately predicted and adjusted, adjustment suggestions can be given in real time through a feedback mechanism, and the safety and the curative effect of individualized medication are ensured.

The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and / or treating dyslipidemia.

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

The invention provides a drug screening and curative effect evaluation method and system based on a glioma organ-like model, and relates to the technical field of biological material analys.The method includes the steps that a three-dimensional fluorescence image of the glioma organ-like model is collected, signal intensity analysis and compensation processing are carried out, a growth feature mapping model is constructed, and the three-dimensional fluorescence image of the glioma organ-like model is obtained; and phenotypic characteristics for representing the glioma organoid heterogeneity are obtained. Inputting the phenotypic characteristics into a drug response evaluation network, and calculating a drug sensitivity score; the drug molecular feature library and the drug collaborative analysis model are combined, the synergistic interaction index of different drug combinations is calculated, the optimal drug combination is screened, the drug administration dosage and the drug administration time sequence are determined in combination with phenotypic features, and finally an individualized treatment scheme is generated. According to the invention, the curative effect of the drug on the glioma organs can be effectively evaluated, and the optimal drug combination and administration scheme can be screened out, so that the accuracy and effectiveness of glioma treatment are improved.

The invention relates to a deep learning method-based pharmacokinetics-pharmacodynamics and reinforcement learning-based propofol administration method and application thereof, a PKPD model is used for simulating the metabolic process of propofol in a human body, and a time dependency relationship and dynamics continuous information are extracted through LSTM and Neural OED; then a nonlinear relation between the propofol drug effect concentration and a clinically observed anesthesia depth index BIS is established through a Kan network, mapping between monitoring information and the anesthesia depth in an operation is rapidly established, a strategy is adjusted in time according to environment changes, and the method is suitable for processing non-standardized complex problems and has good application prospects. And the dosage and the administration scheme of the medicine are individually adjusted, so that the treatment effect is improved.

In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

Provided herein is, among other things, is a method of treating cancer using an improved intermittent dosing regimen for Azenosertib, or a pharmaceutically acceptable salt thereof, administration to achieve a highly efficacious, safe and tolerable dosing regimen to treat many different types of cancers. In one aspect, the method of treating cancer comprises administering a daily dose of Azenosertib, or a pharmaceutically acceptable salt thereof, (e.g., greater than about 350 mg) in accordance with an improved intermittent dosing cycle, wherein the intermittent dosing cycle comprises one or more dosing weeks with each dosing week comprising between about 2-7 consecutive dosing days and between about 1-7 days without dosing. In some embodiments, the intermittent dosing cycle is repeated wherein the dosing weeks are separated by a break of one, two or more weeks. In some aspects, Azenosertib, or a pharmaceutically acceptable salt thereof, is administered as a combination therapy.

Methods of expanding tumor infiltrating lymphocytes (TILs) using a tumor necrosis factor receptor superfamily (TNFRSF) agonist, such as a 4-1BB agonist, a CD27 agonist, a glucocorticoid-induced TNF receptor-related agonist, an OX40 agonist, a HVEM agonist, or a CD95 agonist, and uses of such expanded TILs in the treatment of diseases such as cancer are disclosed herein. In addition, in some embodiments, therapeutic combinations of TILs and TNFRSF agonists useful in the treatment of diseases such as cancer, including compositions, uses, and dosing regimens thereof, are disclosed herein.

The invention discloses an anesthesia depth accurate prediction system and method based on time sequence alignment. The method comprises the steps that a cross-modal joint time sequence characteristic data matrix is acquired and generated; outputting a time sequence alignment feature sample; outputting a future advanced prediction label set; obtaining a first-stage anesthesia depth prediction model; in the first anesthesia depth prediction model training stage, a logic auditing link is introduced, and a self-adaptive online updating model is formed; starting an anti-fact dose simulation module, and outputting a candidate anti-fact administration scheme set; and inputting the candidate anti-factual administration scheme set into a dynamic security constraint optimizer, rejecting non-compliant schemes by the dynamic security constraint optimizer according to single maximum dose limitation, single additional dose and administration times in a minimum administration interval, and outputting an optimal administration suggestion. According to the method, combined classification judgment is carried out on the anesthesia state grade and the change trend of each prediction step, and the sensitivity of clinical risk identification and abnormal situation early warning is effectively improved.

Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

The present disclosure relates to dosing regimens of an HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

The present disclosure relates to a once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same to induce weight loss in humans suffering from fatty liver disease, where the humans may or may not suffer from other complications, such as type 2 diabetes and / or cardiovascular disease / disorder. The dual agonist of the GLP-1R and the GCGR comprises a peptide product of SEQ ID NO. 1 (pemvidude), and a preparation method of the GLP-1R and GCGR dual agonist.

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20 / anti-CD3 bispecific antibody (e.g., mosunetuzumab).

Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

A conversational AI platform for managing remote and hybrid clinical trials for investigational medical interventions. Embodiments of the present disclosure comprise a conversational AI model and an algorithmic logic engine configured to define and implement protocol parameters for dosing schemas, visit schedules, safety thresholds, and eligibility criteria for a clinical trial. An AI agent is configured to deliver mapped voice prompts to participant devices, captures audio responses, transcribe and extract symptom, adherence, or adverse-event data, and pair response data with physiological-sensor or laboratory input data. The logic engine continuously evaluates the combined data to adaptively select dose-escalation or titration instructions and issue follow-up queries while enforcing safety thresholds. All prompts, audio, transcriptions, decisions, and metadata may be immutably timestamped in an electronic record repository accessible via role-based, encrypted connections. Embodiments of the present disclosure provide for real-time, audit-ready trial communications, automated personalized dosing, and enhanced participant safety monitoring.

In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

Provided herein is the use of certain biomarkers, such as tryptophan and metabolites thereof for use in certain treatment methods. Suitable tryptophan metabolites that may serve as useful biomarkers include, for example, kynurenine (Kyn), kynurenic acid (KynA), and quinolinic acid. Such biomarkers may be used in identifying a subject who may benefit from treatment, predicting the responsiveness or monitoring the response of the subject to the treatment, or determining or adjusting the dosing or dosing regimen of the treatment to the subject.

The present invention provides dosing regimens of bispecific antibodies that target both CD3 and CD20 when used in the treatment of lymphoma, such as B cell non-Hodgkin lymphoma (B-NHL).

The invention includes dry powder nintedanib formulation for dispersion and inhalation administration including salts thereof, indolinone derivative or salts thereof and in fixed dose combinations with carrier agents and other active ingredients. The aerosol delivery combination formulation may be administered as an inhaled aerosol over a few actuations or by two or more actuations. Each dose may be administered one or more times daily on a regular or interval daily dosing regimen. The special formulation parameters of the invention include the selection of the salt for complexation with the form of nintedanib used for an isolated dry powder along with particle size distributions and combination with a force control agent for improved aerosol delivery. Methods of the invention include therapeutically effective doses of the described invention used to treat interstitial lung disease.

The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I):or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The invention is a method for treating levodopa naïve patients with Parkinson's disease by orally administering a controlled release levodopa formulation twice a day to the levodopa naïve patient and the method provides an improvement of a patient's motor state as determined by patient's Parkinson's disease diary, provides a reduction of from about 10%-40% in the patient's tremor, dyskinesia, and / or mobility and / or provides a reduction in the patient's Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores by at least 3 points.

The present invention includes dry powder nintedanib formulations for dispersive and inhalation administration, including salts thereof, indolone derivatives or salts thereof, and in fixed dose combinations with a carrier agent and other active ingredients. The aerosol delivery combination formulation may be administered as an inhalation aerosol over several actuations or by two or more actuations. Each dose may be administered one or more times per day according to a regular or interval daily dosing regimen. Specific formulation parameters of the present invention include the selection of salts complexed with the nintedanib form for the isolated dry powder, as well as particle size distribution and in combination with force control agents to improve aerosol delivery. The methods of the invention comprise therapeutically effective doses of the described invention for the treatment of interstitial lung disease.

Provided is a method of treating malignant tumor by an azabicyclic compound, particularly, with eye disorder reduced. The present invention provides a method for treating malignant tumor, comprising administering an effective amount of 3-ethyl-4-[3-(1-methylethyl)-4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-1H-pyrazolo[3,4-b]pyridin-1-yl]benzamide (compound 1) or a salt thereof to a patient in need thereof according to a dosing regimen, wherein the dosing regimen comprises administering the compound 1 or the salt thereof at a dose from 40 mg / body / day to 240 mg / body / day in terms of the amount of the compound 1 for consecutive days, and then providing a withdrawal period of at least 2 days.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.